The Autoimmune Disease Therapeutics Market size was valued at USD 72.05 billion in 2022 and it is expected to be worth around USD 94.87 billion by 2030 growing at a remarkable CAGR of 3.5% over the forecast period 2023-2030.
The autoimmune disease therapeutics market has been experiencing significant growth due to the rising incidence of autoimmune diseases globally. Factors such as genetic predisposition, environmental triggers, and lifestyle changes contribute to the increasing prevalence of autoimmune disorders. The market encompasses a wide range of autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, psoriasis, lupus, type 1 diabetes, and others. Each disease may require specific therapeutic approaches. Biologics, including monoclonal antibodies and other advanced therapies, have become a major focus in autoimmune disease treatment.
Get More Information on Autoimmune Disease Therapeutics Market - Request Sample Report
DRIVERS
Increasing Prevalence of Autoimmune Diseases
Demand for Personalized Medicine
The rising incidence of autoimmune disorders globally is a major driver for the autoimmune disease therapeutics market. Factors such as changes in lifestyle, environmental influences, and genetic predisposition contribute to the growing prevalence
Growing interest in personalized medicine and precision therapies supports the development of tailored treatments for autoimmune diseases, enhancing efficacy and reducing side effects.
RESTRAIN
High Cost of Biologics
Side Effects and Safety Concerns
Complexity of Autoimmune Diseases
The high cost of biologic drugs can be a significant barrier, limiting access for some patients and impacting market growth. Immunomodulatory therapies, including biologics and immunosuppressants, may have side effects and safety concerns, influencing patient and physician preferences. The complexity of autoimmune diseases, involving diverse and interconnected pathways, poses challenges in developing targeted and effective therapeutics.
OPPORTUNITY
Collaborations and Partnerships
Patient-Centric Approaches
Collaborations between pharmaceutical companies, research institutions, and healthcare organizations can facilitate the development of innovative therapies and accelerate market growth.
The shift towards patient-centric approaches, including personalized medicine and patient engagement, creates opportunities for tailored autoimmune disease therapeutics.
CHALLENGES
Regulatory Challenges
Competition and Market Saturation
Access to Healthcare
Meeting regulatory standards and navigating the complex approval process for autoimmune disease therapeutics can be challenging for pharmaceutical companies.
Intense competition in the market and saturation in some segments can pose challenges for companies seeking differentiation and market share.
Disparities in healthcare access and affordability can impact the adoption of autoimmune disease therapeutics, particularly in lower-income regions.
Geopolitical instability can introduce regulatory uncertainties. Changes in political environments may affect regulatory frameworks, approval processes, and market access for pharmaceutical companies.Wars and geopolitical tensions can have broader economic consequences. Economic instability may impact healthcare budgets, healthcare infrastructure, and individuals' ability to afford and access autoimmune disease therapeutics.Ongoing conflicts can divert resources and attention away from research and development efforts in the pharmaceutical industry. This may impact the progress of new therapies and drug discovery for autoimmune diseases.
IMPACT OF ONGOING RECESSION
During a recession, individuals and healthcare systems may face financial constraints. Affordability of healthcare, including the cost of autoimmune disease therapeutics, could become a significant concern. Patients may struggle to afford medications, leading to changes in prescription patterns and potential delays or interruptions in treatment. Governments and healthcare institutions may experience budget constraints during economic downturns. This can affect funding for research and development, public health initiatives, and subsidies for certain medications, potentially impacting the autoimmune disease therapeutics market. Physicians and healthcare providers may reevaluate prescription patterns during a recession. They may opt for more cost-effective treatments or generics, potentially affecting the market share of certain autoimmune disease therapeutics.
Anti-inflammatory
Antihyperglycemics
NSAIDs
Interferons
Others
By Indication
Rheumatic Disease
Type 1 Diabetes
Multiple Sclerosis
Inflammatory Bowel Disease
Other Indications
By Sales Channel
Hospital Pharmacy
Drug Store & Retail Pharmacy
Online Store
.png)
Get Customized Report as per Your Business Requirement - Request For Customized Report
North America
USA
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
REGIONAL ANALYSES
North America, United States and Canada these countries have well-established healthcare systems and high prevalence rates of autoimmune diseases. The market is characterized by the presence of major pharmaceutical companies, a robust pipeline of new therapies, and a focus on biologics and targeted therapies.
Western Europe countries like Germany, France, and the UK have advanced healthcare systems and a significant market for autoimmune disease therapeutics. Biosimilars adoption is notable, and regulatory bodies like the European Medicines Agency (EMA) play a crucial role in market dynamics. Eastern Europe access to advanced therapeutics may vary, and economic conditions can impact market growth. However, there is an increasing focus on improving healthcare infrastructure. Asia-Pacific, China and Japan these countries have a growing market for autoimmune disease therapeutics due to increasing prevalence rates. The regulatory landscape is evolving, and there is a rising emphasis on research and development.
Key Players
The major key players are Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd. (Genentech, Inc.,), Johnson & Johnson, Novartis AG, Pfizer Inc., UCB S.A.and others.
Abbott Laboratories-Company Financial Analysis
In June 2023: AstraZeneca initiated a promising collaboration by entering into an exclusive option and license agreement with Quell Therapeutics. This partnership is geared towards advancing the development of engineered T-regulator (Treg) cell therapies, demonstrating significant potential for providing curative solutions for both Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD).
In January 2023: Researchers at Penn Medicine have achieved notable progress in the pursuit of a personalized treatment for the rare autoimmune condition known as myasthenia gravis (MG). Employing the innovative chimeric antigen receptor (CAR) T cell therapy, commonly utilized in the treatment of specific cancer types, they have identified a potential approach to address this particular autoimmune disease.
| Report Attributes | Details |
| Market Size in 2022 | US$ 72.05 Bn |
| Market Size by 2030 | US$ 94.87 Bn |
| CAGR | CAGR of 3.5% From 2023 to 2030 |
| Base Year | 2022 |
| Forecast Period | 2023-2030 |
| Historical Data | 2020-2021 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Drug Class Type (Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons, Others) • By Indication (Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, Other Indications) • By Sales Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, Online Store) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles |
Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd. (Genentech, Inc.), Johnson & Johnson, Novartis AG, Pfizer Inc., UCB S.A. |
| Key Drivers | • Increasing Prevalence of Autoimmune Diseases • Demand for Personalized Medicine |
| Market Opportunities | • Collaborations and Partnerships • Patient-Centric Approaches |
Ans: The Autoimmune disease therapeutics market is growing at a CAGR of 3.5% From 2023 to 2030.
Ans: The Autoimmune disease therapeutics market is projected to reach USD 94.87 billion by 2030.
Ans: The major key players are Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, and others.
Ans: Increasing prevalence of autoimmune diseases in North America is key driving factor.
Ans: North America holds a substantial market share.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of the Ukraine- Russia war
4.2 Impact of ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4..2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8.5 Others
9.1 Rheumatic Disease
9.2 Type 1 Diabetes
9.3 Multiple Sclerosis
9.4 Inflammatory Bowel Disease
9.5 Other Indications
10.1 Hospital Pharmacy
10.2 Drug Store & Retail Pharmacy
10.3 Online Store
11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 North America Autoimmune disease therapeutics market by country
11.2.2North America Autoimmune disease therapeutics market By Drug Class Type
11.2.3 North America Autoimmune disease therapeutics market By Indication
11.2.4 North America Autoimmune disease therapeutics market By Sales Channel
11.2.5 USA
11.2.5.1 USA Autoimmune disease therapeutics market By Drug Class Type
11.2.5.2 USA Autoimmune disease therapeutics market By Indication
11.2.5.3 USA Autoimmune disease therapeutics market By Sales Channel
11.2.6 Canada
11.2.6.1 Canada Autoimmune disease therapeutics market By Drug Class Type
11.2.6.2 Canada Autoimmune disease therapeutics market By Indication
11.2.6.3 Canada Autoimmune disease therapeutics market By Sales Channel
11.2.7 Mexico
11.2.7.1 Mexico Autoimmune disease therapeutics market By Drug Class Type
11.2.7.2 Mexico Autoimmune disease therapeutics market By Indication
11.2.7.3 Mexico Autoimmune disease therapeutics market By Sales Channel
11.3 Europe
11.3.1 Eastern Europe
11.3.1.1 Eastern Europe Autoimmune disease therapeutics market by country
11.3.1.2 Eastern Europe Autoimmune disease therapeutics market By Drug Class Type
11.3.1.3 Eastern Europe Autoimmune disease therapeutics market By Indication
11.3.1.4 Eastern Europe Autoimmune disease therapeutics market By Sales Channel
11.3.1.5 Poland
11.3.1.5.1 Poland Autoimmune disease therapeutics market By Drug Class Type
11.3.1.5.2 Poland Autoimmune disease therapeutics market By Indication
11.3.1.5.3 Poland Autoimmune disease therapeutics market By Sales Channel
11.3.1.6 Romania
11.3.1.6.1 Romania Autoimmune disease therapeutics market By Drug Class Type
11.3.1.6.2 Romania Autoimmune disease therapeutics market By Indication
11.3.1.6.4 Romania Autoimmune disease therapeutics market By Sales Channel
11.3.1.7 Turkey
11.3.1.7.1 Turkey Autoimmune disease therapeutics market By Drug Class Type
11.3.1.7.2 Turkey Autoimmune disease therapeutics market By Indication
11.3.1.7.3 Turkey Autoimmune disease therapeutics market By Sales Channel
11.3.1.8 Rest of Eastern Europe
11.3.1.8.1 Rest of Eastern Europe Autoimmune disease therapeutics market By Drug Class Type
11.3.1.8.2 Rest of Eastern Europe Autoimmune disease therapeutics market By Indication
11.3.1.8.3 Rest of Eastern Europe Autoimmune disease therapeutics market By Sales Channel
11.3.2 Western Europe
11.3.2.1 Western Europe Autoimmune disease therapeutics market By Drug Class Type
11.3.2.2 Western Europe Autoimmune disease therapeutics market By Indication
11.3.2.3 Western Europe Autoimmune disease therapeutics market By Sales Channel
11.3.2.4 Germany
11.3.2.4.1 Germany Autoimmune disease therapeutics market By Drug Class Type
11.3.2.4.2 Germany Autoimmune disease therapeutics market By Indication
11.3.2.4.3 Germany Autoimmune disease therapeutics market By Sales Channel
11.3.2.5 France
11.3.2.5.1 France Autoimmune disease therapeutics market By Drug Class Type
11.3.2.5.2 France Autoimmune disease therapeutics market By Indication
11.3.2.5.3 France Autoimmune disease therapeutics market By Sales Channel
11.3.2.6 UK
11.3.2.6.1 UK Autoimmune disease therapeutics market By Drug Class Type
11.3.2.6.2 UK Autoimmune disease therapeutics market By Indication
11.3.2.6.3 UK Autoimmune disease therapeutics market By Sales Channel
11.3.2.7 Italy
11.3.2.7.1 Italy Autoimmune disease therapeutics market By Drug Class Type
11.3.2.7.2 Italy Autoimmune disease therapeutics market By Indication
11.3.2.7.3 Italy Autoimmune disease therapeutics market By Sales Channel
11.3.2.8 Spain
11.3.2.8.1 Spain Autoimmune disease therapeutics market By Drug Class Type
11.3.2.8.2 Spain Autoimmune disease therapeutics market By Indication
11.3.2.8.3 Spain Autoimmune disease therapeutics market By Sales Channel
11.3.2.9 Netherlands
11.3.2.9.1 Netherlands Autoimmune disease therapeutics market By Drug Class Type
11.3.2.9.2 Netherlands Autoimmune disease therapeutics market By Indication
11.3.2.9.3 Netherlands Autoimmune disease therapeutics market By Sales Channel
11.3.2.10 Switzerland
11.3.2.10.1 Switzerland Autoimmune disease therapeutics market By Drug Class Type
11.3.2.10.2 Switzerland Autoimmune disease therapeutics market By Indication
11.3.2.10.3 Switzerland Autoimmune disease therapeutics market By Sales Channel
11.3.2.11.1 Austria
11.3.2.11.2 Austria Autoimmune disease therapeutics market By Drug Class Type
11.3.2.11.3 Austria Autoimmune disease therapeutics market By Indication
11.3.2.11.4 Austria Autoimmune disease therapeutics market By Sales Channel
11.3.2.12 Rest of Western Europe
11.3.2.12.1 Rest of Western Europe Autoimmune disease therapeutics market By Drug Class Type
11.3.2.12.2 Rest of Western Europe Autoimmune disease therapeutics market By Indication
11.3.2.12.3 Rest of Western Europe Autoimmune disease therapeutics market By Sales Channel
11.4 Asia-Pacific
11.4.1 Asia-Pacific Autoimmune disease therapeutics market by country
11.4.2 Asia-Pacific Autoimmune disease therapeutics market By Drug Class Type
11.4.3 Asia-Pacific Autoimmune disease therapeutics market By Indication
11.4.4 Asia-Pacific Autoimmune disease therapeutics market By Sales Channel
11.4.5 China
11.4.5.1 China Autoimmune disease therapeutics market By Drug Class Type
11.4.5.2 China Autoimmune disease therapeutics market By Sales Channel
11.4.5.3 China Autoimmune disease therapeutics market By Indication
11.4.6 India
11.4.6.1 India Autoimmune disease therapeutics market By Drug Class Type
11.4.6.2 India Autoimmune disease therapeutics market By Indication
11.4.6.3 India Autoimmune disease therapeutics market By Sales Channel
11.4.7 Japan
11.4.7.1 Japan Autoimmune disease therapeutics market By Drug Class Type
11.4.7.2 Japan Autoimmune disease therapeutics market By Indication
11.4.7.3 Japan Autoimmune disease therapeutics market By Sales Channel
11.4.8 South Korea
11.4.8.1 South Korea Autoimmune disease therapeutics market By Drug Class Type
11.4.8.2 South Korea Autoimmune disease therapeutics market By Indication
11.4.8.3 South Korea Autoimmune disease therapeutics market By Sales Channel
11.4.9 Vietnam
11.4.9.1 Vietnam Autoimmune disease therapeutics market By Drug Class Type
11.4.9.2 Vietnam Autoimmune disease therapeutics market By Indication
11.4.9.3 Vietnam Autoimmune disease therapeutics market By Sales Channel
11.4.10 Singapore
11.4.10.1 Singapore Autoimmune disease therapeutics market By Drug Class Type
11.4.10.2 Singapore Autoimmune disease therapeutics market By Indication
11.4.10.3 Singapore Autoimmune disease therapeutics market By Sales Channel
11.4.11 Australia
11.4.11.1 Australia Autoimmune disease therapeutics market By Drug Class Type
11.4.11.2 Australia Autoimmune disease therapeutics market By Indication
11.4.11.3 Australia Autoimmune disease therapeutics market By Sales Channel
11.4.12 Rest of Asia-Pacific
11.4.12.1 Rest of Asia-Pacific Autoimmune disease therapeutics market By Drug Class Type
11.4.12.2 Rest of Asia-Pacific Autoimmune disease therapeutics market By Indication
11.4.12.3 Rest of Asia-Pacific Autoimmune disease therapeutics market By Sales Channel
11.5 Middle East & Africa
11.5.1 Middle East
11.5.1.1 Middle East Autoimmune disease therapeutics market by country
11.5.1.2 Middle East Autoimmune disease therapeutics market By Drug Class Type
11.5.1.3 Middle East Autoimmune disease therapeutics market By Indication
11.5.1.4 Middle East Autoimmune disease therapeutics market By Sales Channel
11.5.1.5 UAE
11.5.1.5.1 UAE Autoimmune disease therapeutics market By Drug Class Type
11.5.1.5.2 UAE Autoimmune disease therapeutics market By Indication
11.5.1.5.3 UAE Autoimmune disease therapeutics market By Sales Channel
11.5.1.6 Egypt
11.5.1.6.1 Egypt Autoimmune disease therapeutics market By Drug Class Type
11.5.1.6.2 Egypt Autoimmune disease therapeutics market By Indication
11.5.1.6.3 Egypt Autoimmune disease therapeutics market By Sales Channel
11.5.1.7 Saudi Arabia
11.5.1.7.1 Saudi Arabia Autoimmune disease therapeutics market By Drug Class Type
11.5.1.7.2 Saudi Arabia Autoimmune disease therapeutics market By Indication
11.5.1.7.3 Saudi Arabia Autoimmune disease therapeutics market By Sales Channel
11.5.1.8 Qatar
11.5.1.8.1 Qatar Autoimmune disease therapeutics market By Drug Class Type
11.5.1.8.2 Qatar Autoimmune disease therapeutics market By Indication
11.5.1.8.3 Qatar Autoimmune disease therapeutics market By Sales Channel
11.5.1.9 Rest of Middle East
11.5.1.9.1 Rest of Middle East Autoimmune disease therapeutics market By Drug Class Type
11.5.1.9.2 Rest of Middle East Autoimmune disease therapeutics market By Indication
11.5.1.9.3 Rest of Middle East Autoimmune disease therapeutics market By Sales Channel
11.5.2 Africa
11.5.2.1 Africa Transfusion Diagnostics Market by country
11.5.2.2 Africa Autoimmune disease therapeutics market By Drug Class Type
11.5.2.3 Africa Autoimmune disease therapeutics market By Indication
11.5.2.4 Africa Autoimmune disease therapeutics market By Sales Channel
11.5.2.5 Nigeria
11.5.2.5.1 Nigeria Autoimmune disease therapeutics market By Drug Class Type
11.5.2.5.2 Nigeria Autoimmune disease therapeutics market By Indication
11.5.2.5.3 Nigeria Autoimmune disease therapeutics market By Sales Channel
11.5.2.6 South Africa
11.5.2.6.1 South Africa Autoimmune disease therapeutics market By Drug Class Type
11.5.2.6.2 South Africa Autoimmune disease therapeutics market By Indication
11.5.2.6.3 South Africa Autoimmune disease therapeutics market By Sales Channel
11.5.2.7 Rest of Africa
11.5.2.7.1 Rest of Africa Autoimmune disease therapeutics market By Drug Class Type
11.5.2.7.2 Rest of Africa Autoimmune disease therapeutics market By Indication
11.5.2.7.3 Rest of Africa Autoimmune disease therapeutics market By Sales Channel
11.6 Latin America
11.6.1 Latin America Autoimmune disease therapeutics market by country
11.6.2 Latin America Autoimmune disease therapeutics market By Drug Class Type
11.6.3 Latin America Autoimmune disease therapeutics market By Indication
11.6.4 Latin America Autoimmune disease therapeutics market By Sales Channel
11.6.5 Brazil
11.6.5.1 Brazil America Wound Closure By Drug Class Type
11.6.5.2 Brazil America Wound Closure By Indication
11.6.5.3 Brazil America Wound Closure By Sales Channel
11.6.6 Argentina
11.6.6.1 Argentina America Wound Closure By Drug Class Type
11.6.6.2 Argentina America Wound Closure By Indication
11.6.6.3 Argentina America Wound Closure By Sales Channel
11.6.7 Colombia
11.6.7.1 Colombia America Wound Closure By Drug Class Type
11.6.7.2 Colombia America Wound Closure By Indication
11.6.7.3 Colombia America Wound Closure By Sales Channel
11.6.8 Rest of Latin America
11.6.8.1 Rest of Latin America Wound Closure By Drug Class Type
11.6.8.2 Rest of Latin America Wound Closure By Indication
11.6.8.3 Rest of Latin America Wound Closure By Sales Channel
12. Company profile
12.1 Abbott Laboratories
12.1.1 Company Overview
12.1.2 Financials
12.1.3 Product/Services/Offerings
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 AbbVie Inc.
12.2.1 Company Overview
12.2.2 Financials
12.2.3 Product/Services/Offerings
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 AstraZeneca Plc.
12.3.1 Company Overview
12.3.2 Financials
12.3.3 Product/Services/Offerings
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 Bristol-Myers Squibb Company
12.4.1 Company Overview
12.4.2 Financials
12.4.3 Product/Services/Offerings
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 F. Hoffmann-La Roche Ltd.
12.5.1 Company Overview
12.5.2 Financials
12.5.3 Product/Services/Offerings
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 Johnson & Johnson
12.6.1 Company Overview
12.6.2 Financials
12.6.3 Product/Services/Offerings
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 Novartis AG
12.7.1 Company Overview
12.7.2 Financials
12.7.3 Product/Services/Offerings
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 Pfizer Inc.
12.8.2 Financials
12.8.3 Product/Services/Offerings
12.8.4 SWOT Analysis
12.8.5 The SNS View
12.9 UCB S.A.
12.9.1 Company Overview
12.9.2 Financials
12.9.3 Product/Services/Offerings
12.9.4 SWOT Analysis
12.9.5 The SNS View
12.10 Amgen Inc.
12.10.1 Company Overview
12.10.2 Financials
12.10.3 Product/Services/Offerings
12.10.4 SWOT Analysis
12.10.5 The SNS View
13. Competitive Landscape
13.1 Competitive Bench marking
13.2 Market Share Analysis
13.3 Recent Developments
13.3.1 Industry News
13.3.2 Company News
13.3.3 Mergers & Acquisitions
14. Use Case and Best Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Healthcare Contract Management Software Market size was valued at USD 1.68 billion in 2023 and is expected to reach USD 10.75 billion by 2032 at a CAGR of 22.9% during the forecast period of 2024-2032.
The Venous Thromboembolism Treatment Market Size was valued at USD 1.05 Bn in 2023, and is expected to reach USD 2.13 Bn by 2032, and grow at a CAGR of 8.50% Over the Forecast Period of 2024-2032.
The Behavioral Health Software Market Size was valued at USD 2.9 billion in 2023 and is expected to reach USD 11.6 billion by 2031 and grow at a CAGR of 19.0% over the forecast period 2024-2031.
The Biopharmaceutical CMO Market size was valued at USD 15.3 billion in 2023 and is expected to reach USD 58.2 billion by 2032 with a growing CAGR of 16% over the forecast period of 2024-2031.
The Companion Diagnostics Market Size, valued at USD 7.66 billion in 2023, is expected to reach USD 21.15 billion by 2032, with a CAGR of 11.9%.
The Generative AI in Healthcare Market size was valued at US$ 1.7 Bn in 2023 and is estimated to US$ 19.99 Bn by 2032 with a growing CAGR of 31.5% Over the Forecast Period of 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
